Vanda Pharmaceuticals (VNDA) EBIT (2016 - 2025)
Historic EBIT for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to -$40.4 million.
- Vanda Pharmaceuticals' EBIT fell 29257.71% to -$40.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$151.2 million, marking a year-over-year decrease of 27178.55%. This contributed to the annual value of -$151.2 million for FY2025, which is 27178.55% down from last year.
- Latest data reveals that Vanda Pharmaceuticals reported EBIT of -$40.4 million as of Q4 2025, which was down 29257.71% from -$31.3 million recorded in Q3 2025.
- In the past 5 years, Vanda Pharmaceuticals' EBIT registered a high of $12.4 million during Q2 2021, and its lowest value of -$41.0 million during Q1 2025.
- Over the past 5 years, Vanda Pharmaceuticals' median EBIT value was -$6.5 million (recorded in 2023), while the average stood at -$7.9 million.
- Its EBIT has fluctuated over the past 5 years, first soared by 837280.0% in 2021, then crashed by 56082.83% in 2024.
- Quarter analysis of 5 years shows Vanda Pharmaceuticals' EBIT stood at $8.6 million in 2021, then fell by 23.24% to $6.6 million in 2022, then tumbled by 207.01% to -$7.1 million in 2023, then tumbled by 44.9% to -$10.3 million in 2024, then crashed by 292.58% to -$40.4 million in 2025.
- Its EBIT stands at -$40.4 million for Q4 2025, versus -$31.3 million for Q3 2025 and -$38.5 million for Q2 2025.